Active Ingredient(s):Elotuzumab FDA Approved: * November 30, 2015 Pharm Company: *BRISTOL MYERS SQUIBB Category:Cancer
Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is d...
* May have multiple approval dates, manufacturers, or labelers.
Empliciti 300 mg Intravenous Injection, Powder, Lyophilized, for Solution